JP2017523143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523143A5 JP2017523143A5 JP2016572643A JP2016572643A JP2017523143A5 JP 2017523143 A5 JP2017523143 A5 JP 2017523143A5 JP 2016572643 A JP2016572643 A JP 2016572643A JP 2016572643 A JP2016572643 A JP 2016572643A JP 2017523143 A5 JP2017523143 A5 JP 2017523143A5
- Authority
- JP
- Japan
- Prior art keywords
- nhc
- independently selected
- alkyl
- heteroatoms
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011961P | 2014-06-13 | 2014-06-13 | |
| US62/011,961 | 2014-06-13 | ||
| PCT/IB2015/054400 WO2015189791A1 (en) | 2014-06-13 | 2015-06-11 | Auristatin derivatives and conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523143A JP2017523143A (ja) | 2017-08-17 |
| JP2017523143A5 true JP2017523143A5 (enExample) | 2018-07-19 |
| JP6681346B2 JP6681346B2 (ja) | 2020-04-15 |
Family
ID=53491655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572643A Expired - Fee Related JP6681346B2 (ja) | 2014-06-13 | 2015-06-11 | オーリスタチン誘導体およびその抱合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9884817B2 (enExample) |
| EP (1) | EP3154997B9 (enExample) |
| JP (1) | JP6681346B2 (enExample) |
| KR (1) | KR20170016479A (enExample) |
| CN (1) | CN106573956A (enExample) |
| AU (1) | AU2015273098B2 (enExample) |
| BR (1) | BR112016028835A2 (enExample) |
| CA (1) | CA2951368A1 (enExample) |
| EA (1) | EA201692530A1 (enExample) |
| IL (1) | IL248961A0 (enExample) |
| MX (1) | MX2016016515A (enExample) |
| SG (1) | SG11201609462RA (enExample) |
| WO (1) | WO2015189791A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2953976B1 (en) * | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| US10464955B2 (en) * | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| CA2951368A1 (en) * | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| KR20240093751A (ko) * | 2016-12-21 | 2024-06-24 | 노파르티스 아게 | 조혈줄기세포를 제거하기 위한 항체 약물 접합체 |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| JP7429639B2 (ja) * | 2017-11-18 | 2024-02-08 | マガリャエス，ンゾラ デ | 抗体薬物複合体またはその薬学的に許容される塩 |
| EP3828196A4 (en) * | 2019-09-29 | 2022-04-27 | MabPlex International Co., Ltd. | METHOD FOR PREPARING AN INTERMEDIATE ANTIBODY-DRUG CONJUGATE BY ACID METHOD AND APPLICATION THEREOF |
| CN113321702B (zh) * | 2020-02-28 | 2022-08-05 | 国家纳米科学中心 | 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用 |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| CN111675694B (zh) * | 2020-06-28 | 2021-11-26 | 山东大学 | 一种含肟基团的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| CA3241878A1 (en) * | 2021-12-23 | 2023-06-29 | Adcentrx Therapeutics Inc. | Novel auristatin analogs and immunoconjugates thereof |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| CN120309684A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| WO1993003054A1 (fr) | 1991-08-09 | 1993-02-18 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive de tetrapeptide |
| EP0731106B1 (en) | 1993-10-01 | 2004-11-17 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin derivatives |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CN1113066C (zh) | 1995-04-21 | 2003-07-02 | 帝国脏器制药株式会社 | 新型肽衍生物 |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| US8288352B2 (en) * | 2004-11-12 | 2012-10-16 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| DK1912677T3 (da) | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| AR059900A1 (es) | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| JP5933562B2 (ja) | 2010-09-29 | 2016-06-15 | シアトル ジェネティックス， インコーポレイテッド | Ｎ−カルボキシアルキル−アウリスタチンおよびその使用 |
| EP3581206B8 (en) | 2010-10-22 | 2025-02-19 | Seagen Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| WO2012113847A1 (en) | 2011-02-25 | 2012-08-30 | Lonza Ltd | Branched linker for protein drug conjugates |
| US9029406B2 (en) | 2011-03-16 | 2015-05-12 | Seattle Genetics, Inc | N-carboxyalkylauristatins and use thereof |
| BR112013027119A8 (pt) | 2011-04-21 | 2018-03-06 | Seattle Genetics Inc | novos conjugados ligante-droga (adcs) e uso dos mesmos |
| KR102356286B1 (ko) | 2011-05-27 | 2022-02-08 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| JP2013100803A (ja) | 2011-08-09 | 2013-05-23 | Toru Shinohara | 水力発電装置および水力発電システム |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| EP2793947B1 (en) | 2011-12-23 | 2021-02-03 | Innate Pharma | Enzymatic conjugation of polypeptides |
| CA2873112A1 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| EP2855520B1 (en) | 2012-06-04 | 2018-09-26 | Novartis AG | Site-specific labeling methods and molecules produced thereby |
| EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
| JP6636925B2 (ja) * | 2013-12-17 | 2020-01-29 | ノバルティス アーゲー | 細胞障害性ペプチドおよびその抱合体 |
| CA2951368A1 (en) * | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
-
2015
- 2015-06-11 CA CA2951368A patent/CA2951368A1/en not_active Abandoned
- 2015-06-11 JP JP2016572643A patent/JP6681346B2/ja not_active Expired - Fee Related
- 2015-06-11 SG SG11201609462RA patent/SG11201609462RA/en unknown
- 2015-06-11 WO PCT/IB2015/054400 patent/WO2015189791A1/en not_active Ceased
- 2015-06-11 EP EP15732439.3A patent/EP3154997B9/en active Active
- 2015-06-11 BR BR112016028835A patent/BR112016028835A2/pt not_active Application Discontinuation
- 2015-06-11 CN CN201580043354.7A patent/CN106573956A/zh active Pending
- 2015-06-11 EA EA201692530A patent/EA201692530A1/ru unknown
- 2015-06-11 MX MX2016016515A patent/MX2016016515A/es unknown
- 2015-06-11 KR KR1020177000694A patent/KR20170016479A/ko not_active Withdrawn
- 2015-06-11 US US15/317,532 patent/US9884817B2/en active Active
- 2015-06-11 AU AU2015273098A patent/AU2015273098B2/en not_active Expired - Fee Related
-
2016
- 2016-11-14 IL IL248961A patent/IL248961A0/en unknown
-
2017
- 2017-11-27 US US15/822,930 patent/US10280139B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523143A5 (enExample) | ||
| JP2018135343A5 (enExample) | ||
| JP2021513534A5 (enExample) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2012522729A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| RU2020131276A (ru) | Терапевтические соединения и композиции | |
| JP2016520618A5 (enExample) | ||
| JP2015537008A5 (enExample) | ||
| JP2016130266A5 (enExample) | ||
| JP2014515349A5 (enExample) | ||
| JP2014521688A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2016506958A5 (enExample) | ||
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| JP2011500550A5 (enExample) | ||
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| JP2018510139A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2016526558A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2017503833A5 (enExample) | ||
| JP2016540742A5 (enExample) |